Decitabine (Dacogen) for myelodysplastic syndromes

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1247, 2006, Pages 91-92

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; CYTARABINE; ERYTHROPOIETIN; LENALIDOMIDE; DRUG DERIVATIVE;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CHROMOSOME DELETION 5; CONSTIPATION; DIARRHEA; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FEVER; HUMAN; MYELODYSPLASTIC SYNDROME; NAUSEA; SHORT SURVEY; TREATMENT DURATION; TREATMENT RESPONSE; ARTICLE;

AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 39049174864     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. ML Heaney and DW Golde. Myelodysplasia. N Engl J Med 1999; 340:1649.
2. Azacitidine (Vidaza) for myelodysplastic syndrome. Med Lett Drugs Ther 2005; 47:11.
3. Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome. Med Lett Drugs Ther 2006; 48:31.
4. H Kantarjian et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794.
5. H Kantarjian et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2006; August 1 e-pub.